Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis
Severe haemophilia A patients treated by emicizumab prophylaxis can benefit both patients' QoL and economic outcomes compared to those treated by rFVIII prophylaxis.
Authors
- C Bührer (ORCID: https://orcid.org/0009-0007-9006-8787)
- Xiuze Jin
- Jianwei Xuan
- Li Zhou (ORCID: https://orcid.org/0000-0002-3669-8928)
- Han Bao
- Yan Xia
- Ziyi Lin
Institutions
- Roche (Switzerland) (CH)
- Sun Yat-sen University (CN)
- Anhui Medical University (CN)
- London School of Hygiene & Tropical Medicine (GB)
- Roche (China) (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Haemophilia
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1111/hae.70209
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00